Archamps, June 29th , 2022 – Cathay Capital announced its investment in TransCure bioServices, alongside the management team and Financière Arbevel. With this transaction, TransCure bioServices will benefit from Cathay Capital’s healthcare expertise as well as its strategic, and financial support to accelerate its growth and global expansion.

Founded in 2012 and based in Archamps (Haute-Savoie, France), TransCure bioServices is a leading “one-stopshop” preclinical contract research organization (CRO) specialized in advanced preclinical in vivo pharmacology with mouse models of fully reconstituted human immune system (HIS) or human-liver (Hu-liver) addressing various therapeutic areas including immuno-oncology, infectious diseases and inflammatory auto-immune diseases.

Thanks to a unique scientific expertise and proprietary humanization techniques, as well as a track-record of data accumulated over more than 10 years, TransCure bioServices has developed an unrivalled quality of services for a large and international customer base, providing c.70 large pharmas and biotech companies with a full spectrum of analytical testing services. TransCure bioServices capitalizes on fully reconstituted human immune system and human hepatic disease models with humanization rates that overperform market standards, allowing to perform tests with results reliability comparable to clinicals studies outcomes. With 80 employees, of which 20 PhDs, the company has witnessed double-digit organic growth over the last years reaching more than €10m of revenue and has recently been awarded with the AAALAC certification.
With strong experience in the healthcare sector and powered by its global platform, Cathay Capital’s investment will support TransCure bioServices in its next development phase, notably to accelerate its international expansion, the development of new mice model platforms, the increase of production capacities, as well as the strengthening of teams and to execute a focused external growth strategy.